Ligand raises 2025 revenue and EPS guidance after second-quarter royalty growth of 57%
Ligand reported second-quarter 2025 results on August 7, 2025, with total revenues and other income of $47.6 million, up 15% from $41.5 million a year earlier, and GAAP net income of $4.8 million, or $0.24 per diluted share, versus a $51.9 million loss in the same period of 2024. The company raised its full-year 2025 revenue guidance to $200 million to $225 million and its adjusted earnings per diluted share guidance to $6.70 to $7.00, which matters to shareholders because both headline measures improved and the outlook was lifted, though the six-month GAAP net loss of $37.6 million reflects a $44.3 million one-time charge.
Key points
- Q2 2025 royalties were $36.4 million, up 57% from $23.2 million, mainly from Recordati's Qarziba and Travere Therapeutics' Filspari.
- Q2 2025 GAAP net income was $4.8 million, or $0.24 per diluted share, compared with a GAAP net loss of $51.9 million, or $2.88 per share, in Q2 2024.
- Six-month GAAP net loss was $37.6 million, or $1.95 per share, including a $44.3 million one-time charge tied to the Castle Creek Biosciences royalty financing agreement.
- 2025 revenue guidance rose to $200 million to $225 million from $180 million to $200 million; adjusted EPS guidance rose to $6.70 to $7.00 from $6.00 to $6.25.
The filing
Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.